PL1715848T3 - Preparaty mikroemulsyjne zawierające szczególnych antagonistów substancji P - Google Patents
Preparaty mikroemulsyjne zawierające szczególnych antagonistów substancji PInfo
- Publication number
- PL1715848T3 PL1715848T3 PL05707213T PL05707213T PL1715848T3 PL 1715848 T3 PL1715848 T3 PL 1715848T3 PL 05707213 T PL05707213 T PL 05707213T PL 05707213 T PL05707213 T PL 05707213T PL 1715848 T3 PL1715848 T3 PL 1715848T3
- Authority
- PL
- Poland
- Prior art keywords
- antagonists
- particular substance
- microemulsion formulations
- substance
- arylcarbonylamino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402679.5A GB0402679D0 (en) | 2004-02-06 | 2004-02-06 | Organic compounds |
| PCT/EP2005/001166 WO2005074891A1 (en) | 2004-02-06 | 2005-02-04 | Microemulsion formulations comprising particular substance p antagonists |
| EP05707213A EP1715848B1 (en) | 2004-02-06 | 2005-02-04 | Microemulsion formulations comprising particular substance p antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1715848T3 true PL1715848T3 (pl) | 2011-01-31 |
Family
ID=31985813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05707213T PL1715848T3 (pl) | 2004-02-06 | 2005-02-04 | Preparaty mikroemulsyjne zawierające szczególnych antagonistów substancji P |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080254113A1 (pl) |
| EP (1) | EP1715848B1 (pl) |
| JP (1) | JP2007520521A (pl) |
| CN (1) | CN1929817B (pl) |
| AT (1) | ATE475409T1 (pl) |
| AU (1) | AU2005210134B2 (pl) |
| BR (1) | BRPI0507492A (pl) |
| CA (1) | CA2553658A1 (pl) |
| DE (1) | DE602005022558D1 (pl) |
| ES (1) | ES2349647T3 (pl) |
| GB (1) | GB0402679D0 (pl) |
| PL (1) | PL1715848T3 (pl) |
| PT (1) | PT1715848E (pl) |
| RU (1) | RU2397759C2 (pl) |
| WO (1) | WO2005074891A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1938804A1 (en) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| RU2481822C1 (ru) * | 2012-02-21 | 2013-05-20 | Автономная некоммерческая организация "Институт медико-биологических исследований и технологий" (АНО "ИМБИИТ") | Микроэмульсионные композиции для создания трансдермальных и трансмукозальных форм фармацевтических средств и косметических препаратов и способ их получения |
| RU2677346C2 (ru) * | 2013-01-14 | 2019-01-16 | ИнФерст Хэлткэр Лимитед | Композиции и способы для лечения сильной боли |
| EP3086777A1 (en) * | 2013-12-23 | 2016-11-02 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
| DE69804624T2 (de) * | 1997-07-29 | 2002-09-19 | Upjohn Co | Selbstemulgierende formulierung enthaltend lipophile verbindungen |
| AU5624599A (en) * | 1998-08-25 | 2000-03-14 | Lothar Farber | Pharmaceutical uses |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| MY120392A (en) * | 2000-06-08 | 2005-10-31 | Hovid Berhad | A novel drug delivery system : formulation for fat-soluble drugs |
-
2004
- 2004-02-06 GB GBGB0402679.5A patent/GB0402679D0/en not_active Ceased
-
2005
- 2005-02-04 US US10/597,313 patent/US20080254113A1/en not_active Abandoned
- 2005-02-04 AT AT05707213T patent/ATE475409T1/de active
- 2005-02-04 JP JP2006551813A patent/JP2007520521A/ja active Pending
- 2005-02-04 EP EP05707213A patent/EP1715848B1/en not_active Not-in-force
- 2005-02-04 CN CN2005800081031A patent/CN1929817B/zh not_active Expired - Fee Related
- 2005-02-04 WO PCT/EP2005/001166 patent/WO2005074891A1/en active Application Filing
- 2005-02-04 AU AU2005210134A patent/AU2005210134B2/en not_active Ceased
- 2005-02-04 RU RU2006131788/15A patent/RU2397759C2/ru not_active IP Right Cessation
- 2005-02-04 DE DE602005022558T patent/DE602005022558D1/de active Active
- 2005-02-04 ES ES05707213T patent/ES2349647T3/es active Active
- 2005-02-04 PL PL05707213T patent/PL1715848T3/pl unknown
- 2005-02-04 PT PT05707213T patent/PT1715848E/pt unknown
- 2005-02-04 BR BRPI0507492-4A patent/BRPI0507492A/pt not_active IP Right Cessation
- 2005-02-04 CA CA002553658A patent/CA2553658A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2553658A1 (en) | 2005-08-18 |
| BRPI0507492A (pt) | 2007-07-17 |
| WO2005074891A1 (en) | 2005-08-18 |
| CN1929817A (zh) | 2007-03-14 |
| RU2397759C2 (ru) | 2010-08-27 |
| ATE475409T1 (de) | 2010-08-15 |
| PT1715848E (pt) | 2010-10-21 |
| EP1715848B1 (en) | 2010-07-28 |
| CN1929817B (zh) | 2012-04-25 |
| JP2007520521A (ja) | 2007-07-26 |
| ES2349647T3 (es) | 2011-01-07 |
| RU2006131788A (ru) | 2008-03-20 |
| EP1715848A1 (en) | 2006-11-02 |
| AU2005210134A1 (en) | 2005-08-18 |
| DE602005022558D1 (de) | 2010-09-09 |
| AU2005210134B2 (en) | 2008-05-22 |
| GB0402679D0 (en) | 2004-03-10 |
| US20080254113A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| MXPA02011311A (es) | Composicion novedosa. | |
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| RU2006132040A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| TR201820559T4 (tr) | Azelastin içeren kompozisyonlar ve bunların kullanım metotları. | |
| NZ600790A (en) | Combination therapy for copd | |
| WO2008064321A3 (en) | Methods of treating chronic inflammatory diseases using a gm-csf antagonist | |
| MXPA05009007A (es) | Medicamento que comprende un agonista beta2 de accion prolongada altamente potente en combinacion con otros ingredientes activos. | |
| WO2008151235A3 (en) | Compositions for delivering medicaments into the lungs, uses thereof | |
| HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
| EP1773374A4 (en) | AGAINST FGF2 AS AN ACTIVE AGENT FOR THE TREATMENT AND PREVENTION OF ASTHMA AND CHRONIC OBSTRUCTIVE LUNG DISEASE | |
| HUP0401614A2 (hu) | PDE4 inhibitort és antikolinerg hatóanyagot tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MX2009008363A (es) | Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2. | |
| MY145919A (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
| EA200601880A1 (ru) | Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов | |
| PL1715848T3 (pl) | Preparaty mikroemulsyjne zawierające szczególnych antagonistów substancji P | |
| IL165378A0 (en) | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof | |
| WO2005011594A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| WO2007002457A3 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| WO2005011608A3 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR | |
| MX2010012019A (es) | Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2. | |
| EP2323656A4 (en) | PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST | |
| MX2010004529A (es) | Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado. | |
| WO2005011595A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |